Production in India is expected to come fully onstream in September and RDIF expects India to become a major production hub for the Sputnik V vaccine with such companies as Serum Institute of India
Hyderabad firm says it will not take responsibility for the consequences of unauthorised deals, fraudulent financial transactions or sub-standard products resulting from fraud in the name of Sputnik V vaccine
Sputnik V was registered in India under the emergency use authorization procedure on April 12, and vaccination against coronavirus with the Russian vaccine started on May 14.
So far, Dr Reddy’s has received the first consignment of 1.5 lakh doses on May 1 with imported supplies of the first dose.
Hyderabad-based Dr Reddy’s Laboratories has collaborated with RDIF to import the first consignment of Sputnik-V while it is expected that the pharma giant will start manufacturing from its local facilities in India
RDIF CEO Kirill Dmitriev in a virtual press conference recently said he expected over 50 million doses of Sputnik V vaccine to be manufactured in India by this summer.
India has become the 60th country to approve Sputnik V, RDIF, Russia's sovereign wealth fund, said in a statement.
Four companies developing Covid vaccines in India are based in Hyderabad
"In India, we have agreements with four large manufacturers. ...India will produce about 300 million doses or more of the vaccine for us next year," he was quoted as saying to Rossiya 24 TV channel by TASS news agency on Thursday.
Trial will be a multicentre, randomised controlled study, which will include safety and immunogenicity
The Gamaleya Center and RDIF announced on November 24 positive results obtained during the second interim data analysis of the largest double-blind, randomised, placebo-controlled Phase III clinical trials in Russia’s history involving 40,000 volunteers.
According to the RDIF -- Russia's sovereign wealth fund, the vaccine's interim clinical trial results show 95 per cent efficacy on the 42nd day after the first dose.
The confirmation is based on the first interim data from the largest randomised, placebo-controlled Phase-III clinical trials in Russia involving 40,000 volunteers
This will be a multi-centre and randomised controlled study, which will include safety and immunogenicity study, Dr Reddy’s said in a statement.
- Advertisement -